Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.

Oncotarget - 27 Oct 2015

Campesato Luís Felipe, Barroso-Sousa Romualdo, Jimenez Leandro, Correa Bruna R, Sabbaga Jorge, Hoff Paulo M, Reis Luiz F L, Galante Pedro Alexandre F, Camargo Anamaria A

Abstract excerpt

Cancer gene panels (CGPs) are already used in clinical practice to match tumor's genetic profile with available targeted therapies. We aimed to determine if CGPs could also be applied to estimate tumor mutational load and predict clinical benefit to PD-1 and CTLA-4 checkpoint blockade therapy. Whole-exome sequencing (WES) mutation data obtained from melanoma and non-small cell lung cancer (NSCLC) patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Melanoma

Share to Programmed Cell Death 1 Receptor

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 26439694
DOI: 10.18632/oncotarget.5950
PMCID: PMC4741447

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.PMID 26439694Read ↗

Assessment of tumor mutation burden calculation from gene panel sequencing dataSemantic proximity Read ↗

Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer.Semantic proximity Read ↗

Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’Semantic proximity Read ↗

Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncologySemantic proximity Read ↗

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.Semantic proximity Read ↗

Leveraging non-coding regions to guarantee the accuracy of small-sized panel-based tumor mutational burden estimates.Semantic proximity Read ↗

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor boardSemantic proximity Read ↗

The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene PanelSemantic proximity Read ↗

Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.Semantic proximity Read ↗

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.Semantic proximity Read ↗

Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.Semantic proximity Read ↗

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.